Get notified of page updates

Enroll in Research > Research Search & Enroll Tool > Denosumab and Mammographic Density in Premenopausal Women With Dense Breasts (TRIDENT)

Glossary on

off

Printer Friendly Page

Denosumab and Mammographic Density in Premenopausal Women With Dense Breasts (TRIDENT)

Clinicaltrials.gov identifier:
NCT04067726

Prevention

Study Contact Information:

RANKL Inhibition With Denosumab on Mammographic Density in Premenopausal Women With Dense Breasts (TRIDENT)

About the Study

The purpose of this study is to evaluate if denosumab can reduce the breast density of premenopausal women who have dense breasts. Denosumab is an FDA-approved injectable medication that is used to treat and to prevent fractures in cancer patients with bone metastases. This study could help us identify novel ways to prevent breast cancer in younger women.

NOTE: This study is no longer enrolling people

This Study is Open To:

NOTE: This study is no longer enrolling people

This Study is Not Open To:

NOTE: This study is no longer enrolling people